No Data
PharmaResources: 2024 Annual Report
PharmaResources: Summary of the 2024 Annual Report
Hongbo Pharmaceutical (301230.SZ): In 2024, the net income is expected to decline by 54.59% year-on-year and plans to distribute 3.3 yuan for every 10 shares.
On April 23, Glonghui announced that Hongbo Pharmaceutical (301230.SZ) released its annual report for 2024. During the reporting period, the company achieved a revenue of 544.4713 million yuan, an increase of 11.18% compared to last year. With the Federal Reserve's interest rate hike cycle nearing its end, global Biomedical investment and financing data have seen a slight recovery. The company's operating conditions improved in the fourth quarter, achieving both year-on-year and sequential growth in revenue and net income attributable to Shareholders of the listed company. During the reporting period, the net income attributable to Shareholders of the listed company was 17.0832 million yuan, a decrease of 54.59% year-on-year. A dividend of 10 shares will be distributed to all shareholders.
Why We're Not Concerned Yet About PharmaResources (Shanghai) Co., Ltd.'s (SZSE:301230) 30% Share Price Plunge
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
Does PharmaResources (Shanghai) (SZSE:301230) Have A Healthy Balance Sheet?
Declining Stock and Decent Financials: Is The Market Wrong About PharmaResources (Shanghai) Co., Ltd. (SZSE:301230)?
